Pfizer says pandemic could continue until 2024


Pharmaceutical giant Pfizer predicted Friday that the COVID-19 pandemic may not end until 2024, Reuters reports. Also on Friday, the company and its partner BioNTech SE announced plans to delay request for authorization of their COVID-19 vaccine in children ages 2 to 5 "after the shot generated a weaker than expected immune response in a key study," writes The Wall Street Journal.
In a presentation to investors, Pfizer Chief Scientific Officer Mikael Dolsten explained the company "expects some regions to continue to see pandemic levels of COVID-19 cases over the next year or two," per Reuters. Meanwhile, he said, other countries might simultaneously experience COVID on more of an "endemic" level, with "low, manageable caseloads."
By 2024, however, COVID-19 should be endemic globally, Pfizer forecasted.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"When and how exactly this happens will depend on evolution of the disease, how effectively society deploys vaccines and treatments, and equitable distribution to places where vaccination rates are low," Dolsten said. "The emergence of new variants could also impact how the pandemic continues to play out."
Regarding a vaccine for kids ages 2 to 5, Pfzier and BioNTech said they would "begin testing the addition of a third dose in the children, and if successful, would ask U.S. health regulators to authorize use sometime during the first half of 2022," per the Journal.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brigid Kennedy worked at The Week from 2021 to 2023 as a staff writer, junior editor and then story editor, with an interest in U.S. politics, the economy and the music industry.
-
Labubu: the 'creepy' dolls sparking brawls in the shops
Craze for the pint-sized soft toys has reached fever pitch among devotees
-
The top period dramas to stream now
The Week Recommends Heaving bosoms and billowing shirts are standard fare in these historical TV classics
-
Women need more pain management during gynecological procedures
Under the radar Pain should no longer be ignored
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr.: A new plan for sabotaging vaccines
Feature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
-
Five years on: How Covid changed everything
Feature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics